195 related articles for article (PubMed ID: 27107722)
1. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
[TBL] [Abstract][Full Text] [Related]
3. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
4. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.
George EM; Herzog TJ; Neugut AI; Lu YS; Burke WM; Lewin SN; Hershman DL; Wright JD
Gynecol Oncol; 2013 Oct; 131(1):42-5. PubMed ID: 23838036
[TBL] [Abstract][Full Text] [Related]
5. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
[TBL] [Abstract][Full Text] [Related]
6. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis.
Rauh-Hain JA; Starbuck KD; Meyer LA; Clemmer J; Schorge JO; Lu KH; Del Carmen MG
Gynecol Oncol; 2015 Oct; 139(1):84-9. PubMed ID: 26307402
[TBL] [Abstract][Full Text] [Related]
7. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
8. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy.
Athavale R; Thomakos N; Godfrey K; Kew F; Cross P; de Barros Lopes A; Hatem MH; Naik R
Int J Gynecol Cancer; 2007; 17(5):1025-30. PubMed ID: 17466043
[TBL] [Abstract][Full Text] [Related]
9. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
10. Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
Bregar AJ; Alejandro Rauh-Hain J; Spencer R; Clemmer JT; Schorge JO; Rice LW; Del Carmen MG
Gynecol Oncol; 2017 Apr; 145(1):114-121. PubMed ID: 28159409
[TBL] [Abstract][Full Text] [Related]
11. Carcinosarcoma of the ovary-a case series.
Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
[TBL] [Abstract][Full Text] [Related]
12. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
13. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database.
Rauh-Hain JA; Diver E; Meyer LA; Clemmer J; Lu KH; Del Carmen MG; Schorge JO
Gynecol Oncol; 2015 Oct; 139(1):77-83. PubMed ID: 26325526
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
16. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
17. Transitional cell carcinoma of the ovary: a case-control study.
Guseh SH; Rauh-Hain JA; Tambouret RH; Davis M; Clark RM; Boruta DM; Goodman A; Growdon WB; Schorge JO; del Carmen MG
Gynecol Oncol; 2014 Mar; 132(3):649-53. PubMed ID: 24462804
[TBL] [Abstract][Full Text] [Related]
18. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
19. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
[TBL] [Abstract][Full Text] [Related]
20. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]